Liver Transplantation for Hepatocellular Carcinoma beyond the Milan Criteria: A Specific Role for Living Donor Liver Transplantation after Neoadjuvant Therapy
Open Access
Abstract
Purpose: This study was designed to elucidate the various new classifications and the use of LDLT and bridging therapy for HCC in this context beyond the Milan criteria (MC). Methods: The clinical data of patients with HCC outside the MC who underwent LT at Jena University between January 2007 and August 2023 were retrospectively analysed. Eligible patients were classified according to various classification systems. Clinicopathological features, overall and disease-free survival rates were compared between LT and LDLT within the context of bridging therapy. The Results: Among the 245 patients analysed, 120 patients did not meet the MC, and 125 patients met the MC. Moreover, there were comparable overall survival rates between patients outside the MC for LT versus LDLT (OS 44.3 months vs. 28.3 months; 5-year survival, 56.4% vs. 40%; p = 0.84). G3 tumour differentiation, the presence of angioinvasion and lack of bridging were statistically significant risk factors for tumour recurrence according to univariate and multivariate analyses (HR 6.34; p = 0.0002; HR 8.21; p < 0.0001; HR 7.50; p = 0.0001). Bridging therapy before transplantation provided a significant survival advantage regardless of the transplant procedure (OS: p = 0.008; DFS: p < 0.001). Conclusions: Patients with HCC outside the MC who underwent LT or LDLT had worse outcomes compared to those of patients who met the MC but still had a survival advantage compared to patients without transplantation. Nevertheless, such patients remain disadvantaged on the waiting list, which is why LDLT represents a safe alternative to LT and should be considered in bridged HCC patients because of differences in tumour differentiation, size and tumour marker dynamics.Keywords
All Related Versions
This publication has 51 references indexed in Scilit:
- Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinomaHepatology Communications, 2022
- Other “Bridge” Therapies for Liver Transplantation: RFA, TACE, and TARE2019
- Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular CarcinomaCardioVascular and Interventional Radiology, 2018
- The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation studyHepatology, 2016
- Total tumor volume and alpha‐fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validationHepatology, 2015
- Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteriaLiver Transplantation, 2014
- Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: Comparable Survival and RecurrenceLiver Transplantation, 2012
- Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: Living versus deceased donor transplantationHepatology, 2011
- Living Donor Liver Transplantation for Hepatocellular CarcinomaLiver Transplantation, 2009
- Liver Transplantation for Adult Patients with Hepatocellular Carcinoma in KoreaLiver Transplantation, 2005